Filing Flows › Bolt Biotherapeutics (BOLT) › Q2 2025
Bolt Biotherapeutics (BOLT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Bolt Biotherapeutics (BOLT) reported revenue of $1.8M for the second quarter 2025 (Q2 2025), +41% from a year earlier and +48% from the quarter before. Operating margin was -510.5%, net loss $8.6M (474.6% of revenue).
Bolt Biotherapeutics, Q2 2025: revenue $1.8M (+42% year over year), operating margin -510.5%, net loss $8.6M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.8M | +48% | +41% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$8.6M | — | — |
| Operating cash flow | −$9.6M | — | — |
What changed
Revenue was $1.8M in Q2 2025, up 41% year over year and up 48% from the previous quarter.
Operating costs exceeded revenue by $9.2M, an operating margin of -510.5%. Total costs fell 54% while revenue rose 41%. The quarter ended with a net loss of $8.6M, narrower than the previous quarter's $11.0M loss.
Operating cash flow was −$9.6M. Non-cash charges added back $347K of depreciation and amortization and $625K of share-based compensation. Working capital and other items used $2.0M.
Questions
What was Bolt Biotherapeutics' revenue in the second quarter 2025?
Bolt Biotherapeutics (BOLT) reported revenue of $1.8M for the second quarter 2025 (Q2 2025), +41% from a year earlier and +48% from the quarter before.
Was Bolt Biotherapeutics profitable in the second quarter 2025?
Operating loss was $9.2M (-510.5% of revenue) and net loss $8.6M.